|
|
|
|
|
|
|
|
|
|
open access
CONCLUSIONS
The present analysis provides supportive evidence to
inform the potential cost-effectiveness, in the frontline setting, of
the addition of bevacizumab to standard chemotherapy in ovarian cancer
patients at a high risk of progression.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.